OSE Immunotherapeutics : Résultats détaillés encourageants de la phase 2 de lusvertikimab dans la RCH
>Taux de rémission clinique compétitif (17.6% ajusté du pbo) - OSE a dévoilé les résultats détaillés de la partie induction (10 semaines de traitement) de la phase 2 (CoTikis) évaluant lusvertikimab (anti-IL7R) chez c. 130 patients atteints de rectocolite hémorragique (RCH) modérée à sévère, en échec, en perte de réponse ou intolérants à un ou plusieurs traitements antérieurs (corticostéroïdes, IST ou biologiques). Nous savions déjà que l’étude avait atteint son endpo...Ose Immunotherapeutics SA, formerly Orphan Synergy Europe Pharma SA, is a France-based company principally engaged in the clinical stage biotechnological sector. The Company develops immunotherapy products against invasive or metastatic late-stage cancers. The Company offers a technology, called Memopi, which helps the immune system to eliminate malignant cells; it re-educates the body's immunological memory so that the immune system (and particularly T cytotoxic cells) attacks tumor cells by increasing the patient's specific cytotoxic T response against their cancer. The Company's main product, Texopi, is a patented combination of ten epitopes, selected and optimized from five tumor associated antigens.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.